p53 tumor suppressor protein overexpression in osteogenic tumors of dogs

Veterinary Pathology

Volumn 33, Issue 2, 1996, Pages 213-221

  Sagartz, J E ^a   Bodley, W L ^a   Gamblin, R M ^a   Couto, C G ^a   Tierney, L A ^b   Capen, C C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Lovelace Biomedical and Environmental Research Institute   (United States)

Author keywords

Bone; Dogs; Multilobular tumor of bone; Neoplasia; Osteosarcoma; p53; Tumor suppressor gene

Indexed keywords

CANIS FAMILIARIS;

PROTEIN P53; TUMOR PROTEIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; BONE TUMOR; CLASSIFICATION; DOG; DOG DISEASE; METABOLISM; OSTEOSARCOMA; RETROSPECTIVE STUDY;

ANIMALS; BONE NEOPLASMS; DOG DISEASES; DOGS; NEOPLASM PROTEINS; OSTEOSARCOMA; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030100183     PISSN: 03009858     EISSN: None     Source Type: Journal    
DOI: 10.1177/030098589603300211     Document Type: Article

References (49)

1. Andreassen A, Oyjord T, Hovig E, Holm R, Florenes VA, Nesland JM, Myklebost O, Hoie J, Bruland OS, Borresen AL, Fodstad O: p53 abnormalities in different subtypes of human sarcomas. Cancer Res 53:468-471, 1993
2. Baas IO, Mulder JWR, Offerhaus JA, Vogelstein B, Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:13-18, 1994
3. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR: Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 24:469-476, 1993
4. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699-1703, 1991
5. Bodner SM, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF, Linnoila RI: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743-749, 1992
6. Brodey RS, Riser WH: Canine osteosarcoma. A clinicopathologic study of 194 cases. Clin Orthop Relat Res 62:54-64, 1969
7. Caron de Fromentel C, Soussi T: p53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4:1-15, 1992
8. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ: Accumulation of p53 and tumor progression in bladder cancer. N Engl J Med 331:1259-1264, 1994
9. Esrig D, Spruck CH III, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143:1389-1397, 1993
10. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8:531-539, 1988
11. Fontanini G, Vignati S, Bigini D, Merlo GR, Ribecchini A, Angeletti CA, Basolo F, Pingitore R, Bevilacqua G: Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J Pathol 174:23-31, 1994
12. Gannon JV, Greaves R, Iggo R, Lane DP: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595-1602, 1990
13. Ginsberg D, Mechta F, Yaniv M, Oren M: Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 88:9979-9983, 1991
14. Goldschmidt MH, Thrall DE: Malignant bone tumors in the dog. In: Textbook of Small Animal Orthopaedics, ed. Newton CD and Nunamaker DM, pp. 887-898. JB Lippincott, Philadelphia, PA, 1985
15. Hall PA, Lane DP: p53 in tumour pathology: Can we trust immunohistochemistry? - revisited! J Pathol 172: 1-4, 1994
16. Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327, 1993
17. Heyman SJ, Diefenderfer DL, Goldschmidt MH, Newton CD: Canine axial skeletal osteosarcoma. A retrospective study of 116 cases (1986 to 1989). Vet Surg 21: 304-310, 1992
18. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253:49-53, 1991
19. Holm R, Nesland JM: Retinoblastoma and p53 tumor suppressor gene protein expression in carcinomas of the thyroid gland. J Pathol 172:267-272, 1994
20. Iavarone A, Matthay KK, Steinkirchner TM, Israel MA: Germ-line and somatic p33 gene mutations in multifocal osteogenic sarcoma. Proc Natl Acad Sci USA 89:4207-4209, 1992
21. Iggo R, Gatter K, Bartek J, Lane DP, Harris A: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675-679, 1990
22. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S: Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 82:835-840, 1991
23. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991
24. Lane DP, Benchimol S: p53: oncogene or anti-oncogene? Genes Dev 4:1-8, 1990
25. Liu SK, Dorfman HD, Hurvitz AI, Patnaik AK: Primary and secondary bone tumors in the dog. J Small Anim Pract 18:313-326, 1977
26. Masuda H, Miller C, Koeffler HP, Battifora H, Cline MJ: Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 84:7716-7719, 1987.
27. Maxwell SA, Roth JA: Binding of cellular proteins to a conformational domain of tumor suppressor protein p53. Oncogene 8:3421-3426, 1993
28. Michalovitz D, Halevy O, Oren M: Conditional inhibition of transformation of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671-680, 1990
29. Miller CW, Aslo A, Tsay C, Slamon D, Ishizaki K, Toguchida J, Yamamuro T, Lampin B, Koeffler HP: Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res 50:7950-7954, 1990
30. Mulligan M, Matlashewski GJ, Scrable HJ, Cavenee WK: Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA 87:5863-5867, 1990
31. Oglesbee M: Intranuclear inclusions in paramyxovirus-induced encephalitis: evidence for altered nuclear body differentiation. Acta Neuropathol 84:407-415, 1992
32. Oglesbee M, Krakowka S: Cellular stress response induces selective intranuclear trafficking and accumulation of morbillivirus major core protein. Lab Invest 68:109-117, 1993
33. Palmer N: Bones and joints. In: Pathology of Domestic Animals, ed. Jubb KVF, Kennedy PC, and Palmer N, 4th ed., pp. 1-181. Academic Press, San Diego. CA, 1993
34. Pool RR: Tumors of bone and cartilage. In: Tumors in Domestic Animals, ed. Moulton JE, 3rd ed., pp. 157-230. University of California Press, Berkeley, CA, 1990
35. Priester WA, McKay FW: The occurrence of tumors in domestic animals. Natl Cancer Inst Mongr 54:1-210, 1980
36. Probst CW, Ackerman N: Malignant neoplasia of the canine appendicular skeleton. Compend Cont Ed Pract Vet 4:260-270, 1982
37. Santhanam U, Ray A, Sehgal PB: Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 88:7605-7609, 1991
38. Scholz RB, Kabisch H, Weber B: Studies of the RB1 gene and the p53 gene in human osteosarcomas. Pediatr Hematol Oncol 9:125-137, 1992
39. Stopera SA, Bird RP: Immunohistochemical demonstration of mutant p53 tumour suppressor gene product in aberrant crypt foci. Cytobios 73:73-88, 1993
40. Straw RC, LeCouteur RA, Powers BE, Withrow SJ: Multilobular osteochondrosarcoma of the canine skull: 16 cases (1978-1988). J Am Vet Med Assoc 195:1764-1769, 1989
41. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
42. 2-induced canine lung neoplasia. Vet Pathol 30:440, 1993 [Abstract]
43. Toguchida J, Yamaguchi T, Ritchie B, Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T, Kotoura Y, Sasaki MS, Little JB, Weichselbaum RR, Ishizaki K, Yandell DW: Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52:6194-6199, 1992
44. Ueda Y, Dockhorn-Dworniczak B, Blasius S, Mellin W, Wuisman P, Böcker W, Roessner A: Analysis of mutant p53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 119: 172-178, 1993
45. Ueda Y, Dockhorn-Dworniczak B, Blasius S, Wuisman P, Böcker W, Roessner A: Immunohistochemical and immunoelectron microscopic analysis of p53 protein in human osteosarcomas. In: Frontiers of Osteosarcoma Research. Interdisciplinary Survey of Clinical and Research Advances, ed. Novak JF and McMaster JH, pp. 437-441. Hogrefe & Huber, Seattle, WA, 1993
46. Withrow SJ, Powers BE, Straw RC, Wilkins RM: Comparative aspects of osteosarcoma: dog versus man. Clin Orthop Relat Res 270:159-168, 1991
47. Wu X, Boyle JH, Olson DC, Levine AJ: The p53-mdm2 autoregulatory feedback loop. Genes Dev 7:1126-1132, 1993
48. Wynford-Thomas D: p53 in tumor pathology: can we trust immunocytochemistry? J Pathol 166:329-330, 1992
49. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347, 1991